I dont think "Progression-free survival in two co-primary populations" is for P3. On page 33 of the presentation you referenced (thanks for that info as I missed that. Here is a link for others http://www.syntapharma.com/Documents/Synta_Corporate_presentation.pdf ) the co states that the primary endpoint of the P3 portion is not yet set (PFS or OS).
In that (page 33), the co states (for the P2 portion of the Galaxy trial)
Co-primary endpoint, PFS: ITT, KRAS populations ~90% power ITT: 3mo -> 5mo, KRAS: 5wk -> 10wk
So it seems like they consider ITT as the other subpopulation.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.